AstraZeneca’s Movantik Clears FDA; Launch On Hold Pending DEA Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Naloxegol is currently a Schedule II controlled substance due to its structural similarity to another compound; AstraZeneca seeks descheduling of the constipation drug, which labeling states poses no risk of abuse or dependency.
You may also be interested in...
Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago
The latest drug development news and highlights from our US FDA Performance Tracker.
Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik
FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.
Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo
Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.